Puma Bio FDA Advisory Panel Live Blog

Welcome to TheStreet's live blog of the FDA advisory panel reviewing Puma Biotechnology's (PBYI) breast cancer drug neratinib.

This live blog will follow all the action as a group of independent experts hears presentations from the FDA and Puma on the efficacy and safety of neratinib. The panel will then debate the benefits and risks of the drug before taking a vote on whether or not to recommend approval. 

Puma is seeking FDA approval for neratinib as an extended adjuvant breast cancer therapy. That means treating post-surgery breast cancer patients first with one year Herceptin/chemo (standard adjuvant therapy) and then switching them to one year of neratinib.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Stocks

Kohl's Slumps on Tuesday Amid Weak Guidance, Retail Selloff

Kohl's Slumps on Tuesday Amid Weak Guidance, Retail Selloff

Chart of the Day: Is Kohl's a Playable Stock on a Pullback?

Chart of the Day: Is Kohl's a Playable Stock on a Pullback?

Tuesday Turnaround: This Market Is Un-Bear-Able

Tuesday Turnaround: This Market Is Un-Bear-Able

Federated Investors Stock Is Set to Change Direction

Federated Investors Stock Is Set to Change Direction

Market Movers: Federal Reserve Review

Market Movers: Federal Reserve Review